Pierre Fabre Medicament is a French dermo-cosmetics and pharmaceutical company founded in 1962 and based in southwest France near Castres. With global revenue of €3.2 billion in 2025, it ranks as the world's second-largest dermo-cosmetics manufacturer and one of Europe's leading pharmaceutical laboratories. The company operates across 43 locations and distributes products to approximately 130 territories, with international markets representing 71% of revenue.
The company's dermo-cosmetics portfolio includes globally recognized brands such as Eau Thermale Avène, Klorane, Ducray, Dexeryl, A-Derma, René Furterer, and Elgydium. Its pharmaceutical operations span oncology, dermatology, rare diseases, primary care, and family health. Nearly 90% of products are manufactured in France, reflecting a commitment to domestic production and quality standards.
Pierre Fabre's ownership structure is distinctive: the Pierre Fabre Foundation holds 86.3% of capital, while employees hold nearly 10%. This arrangement is designed to preserve the company's independence and long-term vision. The foundation, recognized by the French government as serving the public interest, allocates dividends to fund 35 healthcare-access programs deployed across 22 least-developed countries.
